Cargando…

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers

We investigated the effect of efavirenz on the activities of cytochrome P450 (CYP)1A2, CYP2A6, xanthine oxidase (XO), and N‐acetyltransferase 2 (NAT2), using caffeine as a probe. A single 150 mg oral dose of caffeine was administered to healthy volunteers (n = 58) on two separate occasions; with a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Metzger, Ingrid F., Dave, Nimita, Kreutz, Yvonne, Lu, Jessica B.L., Galinsky, Raymond E., Desta, Zeruesenay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853154/
https://www.ncbi.nlm.nih.gov/pubmed/31339646
http://dx.doi.org/10.1111/cts.12671
_version_ 1783469989265670144
author Metzger, Ingrid F.
Dave, Nimita
Kreutz, Yvonne
Lu, Jessica B.L.
Galinsky, Raymond E.
Desta, Zeruesenay
author_facet Metzger, Ingrid F.
Dave, Nimita
Kreutz, Yvonne
Lu, Jessica B.L.
Galinsky, Raymond E.
Desta, Zeruesenay
author_sort Metzger, Ingrid F.
collection PubMed
description We investigated the effect of efavirenz on the activities of cytochrome P450 (CYP)1A2, CYP2A6, xanthine oxidase (XO), and N‐acetyltransferase 2 (NAT2), using caffeine as a probe. A single 150 mg oral dose of caffeine was administered to healthy volunteers (n = 58) on two separate occasions; with a single 600 mg oral dose of efavirenz and after treatment with 600 mg/day efavirenz for 17 days. Caffeine and its metabolites in plasma and urine were quantified using liquid chromatography/tandem‐mass spectrometry. DNA was genotyped for CYP2B6*4 (785A>G), CYP2B6*9 (516G>T), and CYP2B6*18 (983T>C) alleles using TaqMan assays. Relative to single‐dose efavirenz treatment, multiple doses of efavirenz decreased CYP1A2 (by 38%) and increased CYP2A6 (by 85%) activities (P < 0.05); XO and NAT2 activities were unaffected. CYP2B6*6*6 genotype was associated with lower CYP1A2 activity following both single and multiple doses of efavirenz. No similar association was noted for CYP2A6 activity. This is the first report showing that efavirenz reduces hepatic CYP1A2 and suggesting chronic efavirenz exposure likely enhances the elimination of CYP2A6 substrates. This is also the first to report the extent of efavirenz–CYP1A2 interaction may be efavirenz exposure‐dependent and CYP2B6 genotype‐dependent.
format Online
Article
Text
id pubmed-6853154
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68531542019-12-16 CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers Metzger, Ingrid F. Dave, Nimita Kreutz, Yvonne Lu, Jessica B.L. Galinsky, Raymond E. Desta, Zeruesenay Clin Transl Sci Research We investigated the effect of efavirenz on the activities of cytochrome P450 (CYP)1A2, CYP2A6, xanthine oxidase (XO), and N‐acetyltransferase 2 (NAT2), using caffeine as a probe. A single 150 mg oral dose of caffeine was administered to healthy volunteers (n = 58) on two separate occasions; with a single 600 mg oral dose of efavirenz and after treatment with 600 mg/day efavirenz for 17 days. Caffeine and its metabolites in plasma and urine were quantified using liquid chromatography/tandem‐mass spectrometry. DNA was genotyped for CYP2B6*4 (785A>G), CYP2B6*9 (516G>T), and CYP2B6*18 (983T>C) alleles using TaqMan assays. Relative to single‐dose efavirenz treatment, multiple doses of efavirenz decreased CYP1A2 (by 38%) and increased CYP2A6 (by 85%) activities (P < 0.05); XO and NAT2 activities were unaffected. CYP2B6*6*6 genotype was associated with lower CYP1A2 activity following both single and multiple doses of efavirenz. No similar association was noted for CYP2A6 activity. This is the first report showing that efavirenz reduces hepatic CYP1A2 and suggesting chronic efavirenz exposure likely enhances the elimination of CYP2A6 substrates. This is also the first to report the extent of efavirenz–CYP1A2 interaction may be efavirenz exposure‐dependent and CYP2B6 genotype‐dependent. John Wiley and Sons Inc. 2019-08-12 2019-11 /pmc/articles/PMC6853154/ /pubmed/31339646 http://dx.doi.org/10.1111/cts.12671 Text en © 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Metzger, Ingrid F.
Dave, Nimita
Kreutz, Yvonne
Lu, Jessica B.L.
Galinsky, Raymond E.
Desta, Zeruesenay
CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
title CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
title_full CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
title_fullStr CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
title_full_unstemmed CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
title_short CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
title_sort cyp2b6 genotype‐dependent inhibition of cyp1a2 and induction of cyp2a6 by the antiretroviral drug efavirenz in healthy volunteers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853154/
https://www.ncbi.nlm.nih.gov/pubmed/31339646
http://dx.doi.org/10.1111/cts.12671
work_keys_str_mv AT metzgeringridf cyp2b6genotypedependentinhibitionofcyp1a2andinductionofcyp2a6bytheantiretroviraldrugefavirenzinhealthyvolunteers
AT davenimita cyp2b6genotypedependentinhibitionofcyp1a2andinductionofcyp2a6bytheantiretroviraldrugefavirenzinhealthyvolunteers
AT kreutzyvonne cyp2b6genotypedependentinhibitionofcyp1a2andinductionofcyp2a6bytheantiretroviraldrugefavirenzinhealthyvolunteers
AT lujessicabl cyp2b6genotypedependentinhibitionofcyp1a2andinductionofcyp2a6bytheantiretroviraldrugefavirenzinhealthyvolunteers
AT galinskyraymonde cyp2b6genotypedependentinhibitionofcyp1a2andinductionofcyp2a6bytheantiretroviraldrugefavirenzinhealthyvolunteers
AT destazeruesenay cyp2b6genotypedependentinhibitionofcyp1a2andinductionofcyp2a6bytheantiretroviraldrugefavirenzinhealthyvolunteers